CEISO and KYomed INNOV, two leading French firms specializing in consulting for the development of medical devices (MD, MDN, MD-DIV), announce their merger. Daniel Laune and Gérard Luzergues, long-standing members of the Eurobiomed community and active experts on its Strategic Project Council, outline the lofty ambitions and rationale behind this merger, drawing on their involvement within the cluster.
How does this merger create a unique offering in the market?
Daniel Laune: The merger of CEISO and KYomed INNOV gives rise to a full-service CRO covering the entire medical device development cycle. Project leaders now benefit from a single point of contact coordinating all stages, from economic and regulatory aspects to clinical trials and post-market surveillance. This integrated approach delivers significant time savings and increased efficiency, with a multidisciplinary team sharing a common project history.
What are the strengths of this new entity?
Gérard Luzergues: The new structure is built on two major pillars. First, there is the recognized expertise developed by the CEISO teams in the medical device sector and by KYomed INNOV in digital health. This longevity is synonymous with trust, as evidenced by the loyalty of clients we have supported for over twenty years. On the other hand, a strategic regional presence with three locations—Montpellier, Marseille, and Paris—enabling a proximity that is highly valued by local project leaders. These multi-site locations, situated as close as possible to the regions and clients, constitute a differentiating advantage in the market.
The KYomed INNOV – CEISO group is one of the few organizations in its field to hold ISO 9001, ISO 13485, and Qualiopi certifications for its training programs. Several staff members are recognized as experts by BPI France, and the team includes, notably, an AFNOR trainer who is a former Gmed auditor. These factors attest to the level of professionalism of our teams, which we make available to our clients.
What role did Eurobiomed play in this merger?
Gérard Luzergues: This merger is the culmination of a relationship of trust forged within Eurobiomed. It was through the cluster’s various regular events and thematic committees that we got to know one another and developed a shared vision of support and innovation in healthcare. This trust, built through Eurobiomed, was decisive: faced with several acquisition offers, I chose KYomed INNOV, convinced by the complementary nature of our expertise and our shared values.
Daniel Laune : KYomed INNOV est née d’une idée et initiative du Pôle Eurobiomed en 2010 sous le nom de CR2i avec l’implication de plus de 100 personnes et une cinquantaine de structures publiques et privées. Sans cette impulsion, l’histoire n’aurait jamais existé. 15 ans plus tard et l’obtention d’un financement PIA de l’Etat, Eurobiomed facilite la consolidation d’une CRO française dans la filière des dispositifs médicaux.
What are KYomed INNOV – CEISO’s goals?
Daniel Laune: We aim to become the leading player in France in the field of specialized CROs for all types of medical devices (conventional, implantable, active, digital, and in vitro diagnostic devices). Against the backdrop of industry consolidation, KYomed INNOV – CEISO aims to increase its revenue fivefold over the next five years, with a focus on European expansion. This growth will be driven in particular by cutting-edge innovations based on artificial intelligence applied to clinical trials and training (regulatory and quality) in the medical device sector.
